Somatostatin for uveitic cystoid macular edema (CME)

Ocular Immunology and Inflammation

Volumn 13, Issue 6, 2005, Pages 469-470

  Papadaki, Thekla ^a   Zacharopoulos, Ioannis ^a   Iaccheri, Barbara ^a   Fiore, Tito ^a   Foster, C Stephen ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Cystoid macular edema; Somatostatin; Uveitis

Indexed keywords

ACETAZOLAMIDE; METHOTREXATE; NAPROXEN; OCTREOTIDE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; RETINA MACULA CYSTOID EDEMA; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INJECTIONS, SUBCUTANEOUS; MACULAR EDEMA, CYSTOID; MIDDLE AGED; OCTREOTIDE; SOMATOSTATIN; UVEITIS, INTERMEDIATE;

EID: 28844475122     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940691001964     Document Type: Article

References (7)

1. Dick J. Macular edema. Int Ophthalmol Clin. 1999;39(4):1-18.
2. Lang GE. [Therapy of diabetic retinopathy with somatostatin analogs]. Ophthalmologe. 2004;101(3):290-293.
3. Kuijpers R, Baarsma G, van Hagen P. Treatment of cystoid macular edema with octreotide (Letter). N Engl J Med. 1998;338(9):624-626.
4. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm. 2002;10(4):239-246.
5. Grant M, Caballero S, Millard W. Inhibition of IGF-1 and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue octreotide: a potential treatment for ocular neovascularization. Regul Peptides. 1993;48:267-278.
6. van Hagen PM, Baarsma GS, Mooy CM, Ercoskan EM, ter Averst E, Hofland LJ, Lamberts SW, Kuijpers RW. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol. 2000;143S:S43-S51.
7. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Lowenberg B, Lamberts SW. Somatostatin and the immune and hematopoetic system: a review. Eur J Clin Invest. 1994;24:91-99.